Teicoplanin
"Teicoplanin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycopeptide antibiotic complex from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety.
Descriptor ID |
D017334
|
MeSH Number(s) |
D09.400.420.900 D12.644.233.900
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Teicoplanin".
Below are MeSH descriptors whose meaning is more specific than "Teicoplanin".
This graph shows the total number of publications written about "Teicoplanin" by people in this website by year, and whether "Teicoplanin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2019 | 1 | 0 | 1 | 2020 | 3 | 0 | 3 | 2021 | 1 | 0 | 1 | 2023 | 0 | 1 | 1 | 2024 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Teicoplanin" by people in Profiles.
-
Tegethoff JI, Teitelbaum I, Kiser TH. Rapid and Effective Treatment of Peritonitis in Peritoneal Dialysis Patients with Intravenous Dalbavancin. Am J Case Rep. 2024 Jan 26; 25:e942755.
-
Frazier JD, Stoudenmire LL, Wagner JL, Thomas GM, Steele GM, Henao-Mart?nez AF, Franco-Paredes C, Chastain DB. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2023 Jul; 62(1):106842.
-
Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH. Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. Clin Pharmacokinet. 2022 03; 61(3):363-374.
-
Thomas G, Henao-Mart?nez AF, Franco-Paredes C, Chastain DB. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review. Int J Antimicrob Agents. 2020 Sep; 56(3):106069.
-
Krsak M, Morrisette T, Miller M, Molina K, Huang M, Damioli L, Pisney L, Wong M, Poeschla E. Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review. Pharmacotherapy. 2020 05; 40(5):469-478.
-
Van Matre ET, Teitelbaum I, Kiser TH. Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients. Antimicrob Agents Chemother. 2020 04 21; 64(5).
-
Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019 08 01; 74(8):2405-2416.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|